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In this issue of Clinical Infectious Diseas-
es, Doker et al describe epidemiological
and environmental investigations by a
joint team from the Centers for Disease
Control and Prevention (CDC) and the
Puerto Rico Department of Health into
2 indigenous cases of melioidosis that oc-
curred in 2010 and 2012. The latter case
had positive blood cultures and the pa-
tient survived after treatment with cefe-
pime, which has not previously been
evaluated for treatment of melioidosis;
the former patient died shortly after hos-
pital admission, presumably before cul-
tures were taken, although the evidence
of Burkholderia pseudomallei infection
(immunohistochemistry and polymerase
chain reaction on postmortem tissues)
was convincing. The results of these in-
vestigations conﬁrm irrefutably that me-
lioidosis is endemic in Puerto Rico, with
6 human cases now described and
B. pseudomallei detected in soil, albeit
in only a single sample. The route of
infection in these cases was unclear, al-
though 1 of the patients had engaged in
intravenous drug use which, along with
reporting skin wounds, was 1 of 2 factors
associated with seropositivity among the
patients’ contacts on multivariable logis-
tic regression analysis. Interestingly, this
is the ﬁrst time this association has been
reported since melioidosis was nick-
named “morphine-injector’s septicemia”
nearly 100 years ago [1]. So what are
the implications of this study for local, re-
gional, and global public health?
Burkholderia pseudomallei has appar-
ently been able to persist in the environ-
ment in Puerto Rico for >30 years, as the
ﬁrst case occurred in 1982, but melioido-
sis remains very rare there, or at least is
recognized only rarely. Why is that? If
the incidence of melioidosis throughout
Puerto Rico approached that of northeast
Thailand (12.7/100 000 per year) [2], then
one might expect to see approximately
440 cases every year. Is it possible that
so many cases could be going undiag-
nosed? This seems unlikely, although
there are many instances of melioidosis
being missed by clinicians and microbiol-
ogists unfamiliar with its features [3]. The
CDC investigation found evidence of se-
ropositivity in 6% and 25% of contacts of
the 2010 and 2012 cases, respectively,
suggesting that exposure to B. pseudomal-
lei might actually be quite common in
some places. Serology for B. pseudomallei
is a rather blunt instrument, however.
The indirect hemagglutination assay
(IHA) employed has been widely used
for individual patient diagnosis, and al-
though some culture-positive patients
fail to seroconvert and background sero-
positivity is common among the normal
population of places such as northeast
Thailand, both the IHA and enzyme-
linked immunosorbent assay may be bet-
ter diagnostic tests for melioidosis than
has previously been thought [4, 5]. The
IHA, however, is unstandardized, uses a
crude mix of antigens, and may reﬂect ex-
posure to closely related environmental
saprophytes such as Burkholderia thai-
landensis, so it may overestimate expo-
sure to B. pseudomallei when used for
seroepidemiological studies such as this
[6, 7]. One interesting aspect is that all
the cases of melioidosis so far described
from Puerto Rico have occurred on the
east side of the main island and all the
isolates of B. pseudomallei have been
closely related genetically. This contrasts
starkly with the considerable diversity of
isolates found in the environment in
northeast Thailand [8]. This suggests the
possibility that B. pseudomallei may have
been relatively recently introduced to
Puerto Rico and may remain relatively
geographically restricted, as has been sug-
gested elsewhere [9]. Even within the en-
virons of the residence of the 2012
patient, Doker et al were only able to iso-
late B. pseudomallei from 1 of 20 soil
samples. However, although they used a
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method recommended in recently pub-
lished guidelines [10], which has worked
well with soil from northeast Thailand
[11], recent unpublished evidence sug-
gests it may not work equally well with
all soils and so this investigation may
have underestimated the extent of envi-
ronmental contamination with B. pseudo-
mallei. It would be interesting to see the
results of more extensive soil sampling
throughout Puerto Rico using locally vali-
dated techniques. It is certainly possible
that cases of melioidosis are currently going
unrecognized elsewhere on the island.
If B. pseudomallei is able to survive
in the environment in Puerto Rico and
yet melioidosis is genuinely rare when
compared with some other melioidosis-
endemic areas, why is this? Possible ex-
planations include a lower concentration
of organisms in the soil, less likelihood of
exposure, and greater resistance of the
population to infection. First, average an-
nual temperatures in San Juan are a few
degrees lower than those in northeast
Thailand, whereas the annual rainfall var-
ies considerably across Puerto Rico, so
climatic differences might play a part, as
might the physical, chemical, and biolog-
ical makeup of the soil. Second, only 3%
of the population of Puerto Rico is in-
volved in agricultural work, and rice
farming, an important risk factor for me-
lioidosis in Thailand, is now relatively
uncommon and conﬁned to higher alti-
tudes. Third, fundamental genetic dif-
ferences in susceptibility between the
populations might exist, although diabe-
tes mellitus, the commonest predisposing
factor for melioidosis, is very common
among Puerto Ricans [12]. A better un-
derstanding of the factors involved could
shed important light on the global ecology
and epidemiology of B. pseudomallei.
What of the rest of the Caribbean re-
gion? Although melioidosis is usually
thought of as a disease of southeast Asia
and northern Australia, there is mount-
ing evidence that it is widely distributed
throughout the Caribbean islands, Cen-
tral America, and South America, albeit
with only sporadic cases of infection re-
ported in the literature. It was ﬁrst de-
scribed among sheep, goats, and pigs in
Aruba in 1957 [13]. Subsequent reports
have suggested that B. pseudomallei may
be present in parts of Brazil, British Vir-
gin Islands, Colombia, Costa Rica, Do-
minican Republic, Ecuador, El Salvador,
Guadeloupe, Guatemala, Haiti, Hondu-
ras, Martinique, Mexico, Panama, Peru,
Trinidad, and Venezuela as well as Puerto
Rico [14–24]. It is quite likely that there
could be substantial underrecognition of
the disease in the less well-developed
parts of the region, where laboratory
support for diagnosis is minimal (eg,
neighboring Hispaniola). As laboratory
facilities improve and more bacteria are
identiﬁed accurately by methods such as
matrix-assisted laser desorption/ioniza-
tion–time of ﬂight [25], more of the me-
lioidosis iceberg may emerge. In the
meantime, laboratories in potentially me-
lioidosis-endemic areas should screen all
oxidase-positive gram-negative bacilli
that are not obviously Pseudomonas aer-
uginosa and that are isolated from nor-
mally sterile samples (such as blood
cultures), or in heavy pure growth from
other samples, to exclude B. pseudomal-
lei. Latex agglutination is widely used in
Southeast Asia and has high sensitivity
and speciﬁcity [26], and a new lateral
ﬂow assay looks promising [27].
In recent years, melioidosis has largely
garnered attention in the United States as
a potential bioweapon. Naturally occur-
ring melioidosis, however, is a genuine
problem of the rural poor in some parts
of the tropics, whereas the deliberate
release of B. pseudomallei remains a the-
oretical, and relatively unlikely, possibility.
It is clear that there are some natural res-
ervoirs of B. pseudomallei on America’s
doorstep, although the size of the prob-
lem remains unclear and deserves further
study so that susceptible individuals such
as those with diabetes can be given appro-
priate advice about the avoidance of in-
fection [28]. Physicians should consider
the diagnosis in anyone who has spent
time in the Caribbean who presents
with sepsis, severe pneumonia, or ab-
scesses, particularly if they have predis-
posing factors such as diabetes. Public
health authorities confronted with a sin-
gle case of melioidosis in someone from
the Caribbean should maintain a sense
of proportion and realize that they are
far more likely to have contracted the in-
fection naturally than been the victim of
bioterrorism. Laboratory workers who
have handled the organism before its
identity is recognized should be reassured
that, despite its fearsome reputation, lab-
oratory-acquired melioidosis is extremely
rare and antibiotic prophylaxis, which
has never been shown to be effective any-
way, should only be used judiciously fol-
lowing consensus guidelines [29].
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